Company intelligence
MIMETAS
Human Tissue Models for Better Therapies
About MIMETAS
We strive to contribute to groundbreaking therapies with our screenable, physiologically relevant 3D human disease models. By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases. For more information, visit: www.mimetas.com.
Verified activity
Signals from MIMETAS
7 published signals
Presence & Recognition
MIMETAS is scheduled to attend the 2026 World Molecular Imaging Congress in Salt Lake City on Wednesday, September 9, at the Integrating NAMs into Preclinical Workflow panel discussion.
Reported by MIMETAS
Presence & Recognition
MIMETAS is scheduled to attend the 2026 World Molecular Imaging Congress in Salt Lake City on Tuesday, September 8, at the Industry Sponsored Lunch session.
Reported by MIMETAS
Presence & Recognition
MIMETAS is scheduled to attend the 2026 World Molecular Imaging Congress in Salt Lake City at booth #312.
Reported by MIMETAS
Presence & Recognition
MIMETAS is attending the 2026 World Molecular Imaging Congress in Salt Lake City.
Reported by MIMETAS
Presence & Recognition
MIMETAS will be attending the EUROTOX Congress 2026 in Vienna and presenting a poster on a 3D human blood vessel model for assessing endothelial toxicity and immune activation.
Reported by Amy Mawdesley
Products & Services
MIMETAS is launching a standardized contract research offering called OrganoServices, which provides compound and study requirements, runs experiments on the OrganoPlate platform using validated OrganoReady models, and receives a structured results report.
Reported by MIMETAS
Presence & Recognition
MIMETAS is attending EuroTox 2026 to discuss organ-on-a-chip microfluidics and human relevant models for drug discovery teams.
Reported by MIMETAS